Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

Eric Van Cutsem(Universitair Ziekenhuis Leuven), Geert D’Haens(Amsterdam University Medical Centers), David Cunningham(Royal Marsden NHS Foundation Trust), A Stone(Stone Age Institute), J-Y Douillard(AstraZeneca (United Kingdom)), Jane Robertson(Cancer Research UK), Ralph Wong(CancerCare Manitoba)
British Journal of Cancer
January 8, 2013
10.1038/bjc.2012.545
Cited by 50

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k